Boston Scientific misses view as stent sales slide
119061
Boston Scientific Corp.  posted a lower-than-expected quarterly profit on Friday as sales of its flagship drug-eluting heart stents fell by 32 percent.
586348
As part of a federal inquiry into drug and medical-device marketing, Boston Scientific Corp. was asked by Congress last week to submit to investigators internal documents, marketing plans, and clinical data related to its top-selling product, the Taxus drug-coated stent.
503333
Boston Scientific Corp. stock rose more than 5 per cent Wednesday after company executives called a recent recall of its Taxus heart stents a blip and said most of the lost market share has already been recovered.
588272
Boston Scientific Corp. shipped millions of dollars worth of coronary stents in fall 1998 even after company officials learned that the medical devices had high failure rates and may not have met specifications approved by the Food and Drug Administration.
472694
Novartis AG lowered its full-year results outlook as generic competition pressured sales of a key blood-pressure drug, and said U.S. regulators had delayed the approval process for an important cancer treatment.
632359
Shares of Atherogenics Inc. opened down 7.2 percent on the Nasdaq Wednesday following a pre-market report that the drug developer is abandoning further clinical trials of its AGIX-4207 treatment for rheumatoid arthritis.
471001
Boston Scientific Corp. said Monday that it received Food and Drug Administration clearance to market a device designed to lower the risk of heart attacks during angioplasty and stenting procedures.
90989
The medical device maker reported a third-quarter loss of $272 million on charges related to acquisitions and asset sales, as the companyâs top-selling stent continued to slump.
405260
Johnson &amp; Johnson is picking a price fight over drug-coated stents. Does Boston Scientific Corp. need to respond?
685095
Johnson & Johnson's drug-coated stent  slightly outperformed Boston Scientific's version in reopening  arteries that had been clogged by lesions following the earlier  insertion of bare-metal stents, a study said on Tuesday.
352279
Expensive drug-coated stents -- used to prop open clogged coronary arteries -- are not worth using in many patients, Swiss researchers said on Friday.
353033
Shares plunge after company says its vein graft treatment failed to show benefit in late-stage test. CHICAGO  - Biotechnology company Corgentech Inc.
550945
The catheter that triggered three safety recalls by Boston Scientific Corp. of its best-selling Taxus coronary stent after being linked to three deaths and 47 injuries had not been subjected to the rigors of a human clinical trial, FDA records show.
395590
Johnson & Johnson hopes the results will aid its drive to erode Boston Scientific's dominance in the $5 billion market for drug-coated stents.
753051
Johnson &amp; Johnson and Boston Scientific, the top makers of drug-coated heart stents, both released studies saying their $2,200 devices are safer than bare-metal stents that cost half as much. The studies capped three days of debate at Europe's biggest medical conference, the World Cardiology Congress in Barcelona, sparked by independent researchers who said bare-metal stents were safer. The Boston ...
139261
Boston Scientific Corp. said yesterday it has won back the market share that its flagship cardiac stent system held before three safety recalls reduced doctors&#39; orders of the product.
512814
Boston Scientific Corp. said yesterday it sold $8.3 million worth of its Taxus drug-coated cardiac stents per day this month, a record level the Natick medical-devices giant said demonstrates it has won back doctors' confidence after three recalls.